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Abstract
 Objective—(1) Examine relationships between persistent hypogonadotropic hypogonadism 
(PHH) and long-term outcomes after severe traumatic brain injury (TBI); (2) determine if sub-
acute testosterone levels can predict PHH.
 Setting—Level 1 trauma center at a university hospital.
 Participants—Consecutive sample of men with severe TBI between 2004 and 2009.
 Design—Prospective cohort study.
 Main Measures—Post-TBI blood samples were collected during week 1, every 2 weeks until 
26 weeks, and at 52 weeks. Serum hormone levels were measured, and individuals were 
designated as having PHH if ≥50% of samples met criteria for hypogonadotropic hypogonadism. 
At 6 and 12 months post-injury, we assessed global outcome, disability, functional cognition, 
depression, and quality-of-life.
 Results—We recruited 78 men; median (IQR) age was 28.5 (22–42) years. 34 patients (44%) 
had PHH during the first year post-injury. Multivariable regression, controlling for age, 
demonstrated PHH status predicted worse global outcome scores, more disability, and reduced 
functional cognition at 6 and 12 months post-TBI. Two-step testosterone screening for PHH at 12–
16 weeks post-injury yielded a sensitivity of 79% and specificity of 100%.
 Conclusion—PHH status in men predicts poor outcome after severe TBI, and PHH can 
accurately be predicted at 12–16 weeks.
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 Introduction
Traumatic brain injury (TBI) results in 2.5 million hospital visits annually in the United 
States (US).1 Men are at an increased risk to sustain a TBI in the US, with an annual 
incidence of 932/100,000, compared to 720/100,000 in women.2 Further, ~1.1% of 
Americans live with TBI-related disabilities.3 Individuals with TBI are at high risk for 
developing hypothalamic-pituitary deficiencies, including hypogonadotropic hypogonadism 
(HH).4 Hypogonadism shares many symptoms with TBI (e.g. lack of energy, poor 
concentration, and mood disturbances), making it difficult for clinicians to assess and 
diagnose this problem in individuals recovering from TBI. Prevalence estimates for chronic 
hypogonadism after TBI vary widely, from 8–41%, likely due to differences with time of 
screening, injury severity, and study design.5–7 Most prior studies use single laboratory 
measurements to screen for HH, even though clinical guidelines generally recommend 
repeat testosterone testing for diagnosis if an initial level is found to be low, especially when 
symptoms are non-specific.8 Thus, multiple hormone measurements may more accurately 
determine hypogonadism status. Yet longitudinal data characterizing hormone levels across 
acute, sub-acute, and chronic phases of TBI recovery are limited.
Emerging evidence suggests that individuals with hypogonadism post-TBI may have poorer 
long-term outcomes than those without this complication. Retrospective studies involving 
men with hypogonadism upon presentation to inpatient rehabilitation after TBI have yielded 
both positive and negative results on testosterone associations with functional outcomes.9,10 
A prospective study of 72 patients entering inpatient TBI rehabilitation (mean 250d post-
TBI) reported that those with hypogonadism exhibited worse functional dependence, 
disability, and cognitive function at discharge compared to individuals without 
hypogonadism.11 Testosterone and gonadotropin serum levels were also positively correlated 
with visuoconstructional abilities in a cross-sectional study one year post-TBI.12 In a 
previously reported small cohort (N=38) of men with severe TBI,6 individuals with 
persistent hypogonadotropic hypogonadism (PHH) over the first year after TBI had worse 
disability, cognitive function, and neurological outcomes at 6 and 12 months post-injury. 
Although these data support that hypogonadism contributes to poor recovery post-TBI, 
clinical predictors about which patients will develop hypogonadism have not been identified, 
and relevant screening windows post-TBI have not been established.
The present study builds upon previous work by studying a larger prospective cohort of men 
with severe TBI to: 1) determine the time course of serum sex hormone levels over the first 
year post-TBI; 2) confirm prior findings regarding relationships between hypogonadism and 
multidimensional outcomes at 6 and 12 months post-TBI; and 3) develop a novel two-step 
screening algorithm using sub-acute testosterone levels to predict PHH.
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 Materials and Methods
 Study Design and Population
The local Institutional Review Board approved this research. We conducted a prospective 
cohort study that consecutively recruited patients presenting to a level 1 trauma center 
(defined by Glasgow Coma Scale [GCS] ≤8 at presentation and confirmed computed 
tomography findings). The GCS is the standard scale used to categorize TBI severity.13 This 
analysis included men aged 16–70 years in whom we were able to collect at least two 
subacute (>1 week) blood samples. Individuals were excluded if they had a history of 
hypothalamic or pituitary tumors, orchiectomy, luteinizing hormone (LH) therapy, or 
untreated thyroid disease prior to injury. Informed consent was provided by next-of-kin. 
Subjects were admitted to a neurotrauma intensive care unit and treated according to the 
Brain Trauma Foundation’s Guidelines for the Management of Severe Head Injury.14 
Demographic data (age, body mass index [BMI], race, and education) were recorded. 
Clinical data obtained included GCS (best score in 24 hours), Injury Severity Score (ISS), 
length of hospital stay, mechanism of injury, and acute stay neuroradiology reports. Fourteen 
healthy male volunteers (median age, 21.5 y; range, 19–58 y), without history of head injury, 
neurological disorder, or endocrine disorder, had serum samples drawn for hormone analysis 
to serve as controls.
 Hormone Analysis and Hypogonadism Definition
Blood samples were collected daily when possible for the first week after TBI. Blood was 
collected up to every two weeks for six months, and again at 52 weeks post-injury. Since 
previous data show acute hypogonadism takes ≥2 days to manifest post-TBI,15 we averaged 
individuals’ hormone levels measured days 3–7 and assigned this value as the week 1 value. 
Upon collection, samples were centrifuged, aliquoted in polypropylene cryovials, and stored 
at −80 °C until analysis.
Serum testosterone (25μl samples) was measured in duplicate using radioimmunoassay with 
the Coat-A-Count® In-vitro Diagnostic Test Kit (Siemens Healthcare Diagnostics). Kits 
included a solid-phase 125I radioimmunoassay designed for direct, quantitative 
measurements of each hormone. Serum LH levels were measured in duplicate using a highly 
sensitive fluoroimmunometric assay (Delfia, Perkin-Elmer-Wallac). Inter-assay and intra-
assay coefficients of variation were <10%. Samples with out of range (low) levels were 
assigned the detection limit of the respective assay.
We prospectively defined PHH based on criteria defined in previous work and used serial 
hormone measurements to determine PHH status in this study.6 Individuals were designated 
as having PHH if ≥50% of their samples had testosterone and LH values meeting criteria for 
hypogonadotropic hypogonadism (testosterone <10 nmol/L [minimum normal level] with 
LH <5.6 IU/L [maximum normal level]). These cut-offs are the medical center’s pathology 
lab reference values.
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At 6 and 12 months, trained assessors obtained information on functional outcome, 
depression, quality of life (QOL), and administered a comprehensive cognitive battery.
Functional outcome measures included the Glasgow Outcome Scale (GOS),16 Disability 
Rating Scale (DRS),17 and Functional Independence Measure (FIM).18,19 We dichotomized 
individuals’ GOS scores into favorable outcome (scores 4–5) or unfavorable outcome 
(scores 2–3) for analysis. All individuals were alive at 12 months. The five cognition 
questions of FIM were analyzed separately (FIM-Cog), assessing comprehension, 
expression, social interaction, problem solving, and memory, with total FIM-Cog scores 
ranging from 5–30.
Depression was assessed using the PHQ-9, a self-administered depression symptom 
screening tool that derives its testing items directly from the American Psychiatric 
Association’s Diagnostic and Statistical Manual of Disorders, Fourth Edition diagnostic 
criteria for major depressive disorder.20 We categorized individuals as depressed if they 
endorsed ≥5 symptoms on the PHQ-9, including one of the cardinal symptoms (little interest 
or pleasure in doing things; or feeling down, depressed, or hopeless). The PHQ-9 is a 
validated measure of depressive symptoms post-TBI.21 In addition, we used responses to 
question 4 on the PHQ-9 (“feeling tired or having little energy”) as a measure representing a 
physical symptom of hypogonadism.
In order to assess the impact of PHH status on QOL, we used two outcome measures: 
Perceived Quality of Life (PQOL) and Percent Back to Normal. The PQOL is an 18-item 
questionnaire that quantitatively measures QOL by asking individuals to assess different life 
domains on a scale of 0–100, with higher scores indicating better QOL.22 Individuals’ scores 
for these questions were averaged for analysis. The Percent Back to Normal measure, 
previously used in TBI,23 is a single question asking individuals how close they feel to being 
back to normal, on a scale of 0–100.
We conducted a comprehensive cognitive testing battery, described previously,24 consisting 
of eight tests from a larger neuropsychological battery examining attention, language 
fluency, memory, and executive function. Tests of attention included the Trail Making Test A 
and the Digit Span sub-test of the Wechsler Adult Intelligence Scale-R (WAIS-R).25,26 
Language fluency tests included the Controlled Oral Word Association test27 and the Delis-
Kaplan Executive Function Systems Verbal Fluency test.28 To test memory, we used the 
Rey-Osterreith Complex Figure Task and the California Verbal Learning Test II.29,30 
Executive function was measured by the Trail Making Test B and the Stroop Color and 
Word Test.25,31 Each test was scored in a standardized manner, compared to normative data, 
and reported as a T-score. T-scores for individual tests were then averaged to produce one 
aggregate Cognitive Composite score for each individual.
 Statistical Analysis
All variables were assessed for normality using the Shapiro-Wilk test. Normally distributed 
data were expressed as mean ± standard deviation (SD). Descriptive statistics for skewed 
data were reported as median (interquartile range[IQR]), unless otherwise stated. Mann-
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Whitney U tests were used to conduct group comparisons for: DRS, FIM, FIM-Cog, and 
lack of energy (question 4 of PHQ-9) scores. Independent two-tailed t-tests were used to 
compare the Cognitive Composite scores and hormone levels. Chi-square tests were used for 
GOS outcome and depression status. Outlier hormone levels were removed if they were 
greater than 5x the IQR above the 75th percentile at each time point. Demographic/clinical 
characteristics associated (p<0.2) with outcome measures and PHH status in bivariate 
analysis were analyzed using linear or logistic multivariable regression. Odds ratios (OR) 
and 95% confidence intervals (CI) are reported for logistic regression results, and regression 
coefficients (β) with standard error (SE) are reported for linear regression results.
We developed a two-step testing process (screening test followed by a confirmatory test) for 
predicting PHH status using receiver operating characteristic (ROC) curve analysis with 
testosterone serum levels drawn 12–16 weeks post-injury. This time window is consistent 
with 2005 consensus guidelines on post-traumatic hypopituitarism screening, which 
recommend initial screening for hormone deficiencies at 3 months post-TBI.32 For this 
analysis, we included individuals with at least two testosterone values during the four week 
period. While LH and testosterone were concurrently used in defining PHH, only 
testosterone was used in ROC curve analysis since only a single continuous measure can be 
used to determine cutpoints for sensitivity and specificity assessments. We chose 
testosterone given that this marker was most often below clinical reference ranges with our 
PHH categorization strategy. This is still expected to be representative of PHH considering 
primary hypogonadism is rare in younger populations,33 and all group mean LH values were 
within normal clinical range. A screening ROC curve was generated using individuals’ first 
testosterone value in the time period to find a cut-off testosterone value with 100% 
sensitivity for determining PHH status. From there, individuals with testosterone levels 
below this screening cut-off were used to generate a confirmatory ROC curve analysis with a 
second, subsequent serum testosterone value in the 12–16 week time period being evaluated 
to predict PHH status. A confirmatory test cut-off was determined with 100% specificity. 
This cut-off was chosen to create a clinical testing protocol to identify, without false 
positives, individuals with PHH who may benefit from treatment. Post-hoc cross-sectional 
analyses were conducted to further analyze individuals in the PHH group that had hormone 
measurements at 6 and 12 months. These analyses compared frequency and multi-
dimensional outcomes among those that met hypogonadotropic hypogonadism (HH) criteria 
specifically at 6 or 12 months post-injury vs. those that did not.
Bivariate analyses and ROC curve analysis were conducted using SPSS Version 22.0 
(Armonk, NY), and multivariable analyses were conducted with SAS Version 9.4 (Cary, 
NC). P-values <0.05 were considered statistically significant.
 Results
 Demographics and characteristics of study sample
Demographic and clinical information is reported in Table 1 for the 78 men recruited. The 
PHH group (median, 35 years) was 11 years older than the non-PHH group (median, 24 
years, p=0.04). Groups had similar BMI, education level, and race. Injury and clinical 
characteristics, including GCS, ISS, length of hospital stay, mechanism of injury, and 
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radiographic injury types, were also similar, with the exception of the PHH group having 
only 2 individuals (6%) with diffuse axonal injury compared to 16 (36%) in the non-PHH 
group (p=0.002). Control subjects did not differ from study participants in age (p=0.16).
Neuroimaging reports for computed tomography (CT) and/or magnetic resonance imaging 
(MRI) during acute hospital stay were available for 74 men. One had subacute hemorrhage 
in the left thalamus and hypothalamus on MRI nine days post-injury. The remaining 73 
individuals had no radiographic evidence of pituitary or hypothalamic injury.
Medication data was available at 6 months (n=72) and 12 months (n=57). None of these 
individuals were on exogenous testosterone.
 Serum hormone levels
Thirty-four individuals (44%) had PHH. A total of 618 samples were collected between 2–
52 weeks post-TBI. An additional 152 samples were collected on days 3–7 post-injury and 
averaged to provide a week 1 value for each individual. Two testosterone values and one LH 
value were removed as outliers. The time-course by PHH status for serum testosterone and 
LH is presented in Figure-1. The control group mean±SD testosterone level (n=14) was 
11.057±7.557 nmol/L, and LH level (n=7) was 4.559±2.473 IU/L. PHH group testosterone 
levels were significantly lower than those of the non-PHH group at week 1 (p<0.05) and 
from weeks 6–52 (p<0.001), but were similar at weeks 2–4. While starting in the low-
normal range, LH levels were within the normal reference range at all weeks for both PHH 
and non-PHH groups. LH levels were lower in the PHH group at weeks 10–16 and 24 
(p<0.05).
 6 and 12 month cross-sectional HH assessment
Among those in the PHH group with cross-sectional hormone levels at 6 and 12 months, 13 
individuals (65%) met and 7 individuals (35%) did not meet HH criteria at 6 months. 12 
individuals (71%) met and 5 individuals (29%) did not meet HH criteria. Individuals who 
met HH criteria at 6 and 12 months did not significantly vary (p>0.05 for all comparisons) 
from those who did not on any of the multidimensional outcomes measured in this study 
(GOS, DRS, FIM, FIM-Cog, and lack of energy).
 PHH association with outcomes
Bivariate outcome associations with PHH status are shown in Table-2. Compared to the non-
PHH group, the PHH group exhibited worse FIM scores 6 and 12 months, worse FIM-COG 
scores at 6 and 12 months, worse DRS scores at 12 months, and more commonly endorsed a 
lack of energy on the PHQ-9 at 12 months (p<0.05, all comparisons). Groups did not differ 
by depression status, PHQ-9 scores, PQOL, Percent Back to Normal, or cognitive composite 
scores, including all cognitive subtest scores. Trends were noted for GOS at 6 and 12 months 
and DRS at 6 months.
Age was the only demographic variable that correlated (p<0.2) with both PHH status and 
any outcome (data not shown). Multivariable analyses were thus adjusted for age (Table-3). 
Those with PHH had greater than a 3-fold increased risk of having an unfavorable GOS 
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outcome at 6 and 12 months compared to those in the non-PHH group (p<0.05, both 
comparisons). Further, PHH was a strong predictor of worse DRS scores, where adjusted 
mean scores were 3.2 points higher among those with PHH compared to non-PHH (p<0.05, 
both comparisons). PHH also significantly predicted worse FIM scores at 6 and 12 months, 
where, after age adjustment, those with PHH scored at least 18 points lower than those with 
non-PHH (p<0.05, both comparisons). Similarly, adjusted mean FIM-Cog scores were at 
least 6.7 points lower for the PHH group than the non-PHH group at 6 and 12 months 
(p<0.01, all comparisons). Finally, the PHH group reported having a lack of energy (PHQ-9 
question 4) more often at 12 months, such that there adjusted mean scores were 0.6 points 
higher (range 0–3) than the non-PHH group (p=0.03).
 PHH prediction and ROC curve analysis
Forty individuals (51%) had ≥2 blood samples during the proposed PHH screening period 
(12–16 weeks). Of these individuals, 14 (35%) had PHH. Using the first testosterone value 
obtained in the screening period for these 40 individuals, the ROC curve analysis area under 
the curve (AUC) was 0.915 (95% CI, 0.831–0.999) (Figure-2A), with a 100% sensitivity at a 
cutoff value of 13.47 nmol/L. Seventeen individuals were above this cutoff and categorized 
as not having PHH, while 23 individuals were then included in the second step confirmatory 
test. For this second testosterone measurement in the screening period for these 23 men, the 
AUC was 0.913 (95% CI, 0.784–1.000) as shown in Figure-2B. A corresponding cutoff of 
9.05 nmol/L had 100% specificity and 78.6% sensitivity. The positive predictive value was 
100%, and the negative predictive value was 90%.
 Discussion
This prospective cohort study undertakes the most extensive longitudinal assessment of post-
traumatic hypogonadism currently available in the literature. We report that PHH in men 
after severe TBI is associated with worse functional outcomes compared to men who do not 
develop PHH. Further, two-step testing of testosterone levels 12–16 weeks post-injury 
predicts PHH status, providing a novel, accurate testing method for long-term hypogonadism 
after TBI.
PHH prevalence after severe TBI in this cohort was 44%, larger than prior estimates.5 While 
others have used single serum measurements to define hypogonadism,11,34,35 our PHH 
categorization captures a longitudinal definition of hypogonadism, establishing the 
persistence of hypogonadism for some individuals after TBI. Our multi-measure algorthism 
may more precisely and accurately reflect men’s hypogonadism status over the first year 
post-injury. Our cohort consisted of men with severe TBI, and more severe TBI may confer 
higher hypogonadism risk.36 Serial hormone measurements up to 1yr post-TBI confirmed 
prior data6 showing uniformly low testosterone levels at weeks 1, 2, and 4, followed by 
testosterone recovery in the non-PHH group and sustained hypotestosteronemia in the PHH 
group by week 6. Some literature suggests withholding screening/diagnosis of post-
traumatic hypogonadism until 1yr post-TBI, since self-recovery may occur during this 
time.32,34 However, our data suggest that recovery of testosterone levels begins ~6 weeks 
post-TBI. Normal range LH levels at all time-points suggest that hypothalamic-pituitary 
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suppression is uniform during the first 4 weeks post-TBI which then resolves in some, but 
not all individuals. Traditionally, hypopituitarism after TBI has been attributed to injury 
and/or ischemia of the pituitary gland or infundibulum.37 Pituitary abnormalities on acute 
MRI have been noted in 30% of individuals post-TBI,38 and a small study (N=22) found 
post-traumatic hypopituitarism to be associated with pituitary abnormalities on CT 
conducted long after TBI (mean 17.4y).39 Radiographic pituitary abnormalities were not 
detected in our cohort, which may reflect less stringent study of the pituitary in clinical 
practice than in careful research protocol examination. Post-traumatic autoimmunity to CNS 
proteins is an emerging area of research.40,41 Recent data suggest that autoimmunity to 
pituitary antigens develops after TBI42; more data are needed to determine how 
autoimmunity development after TBI might contribute to PHH.
Our findings corroborate a growing literature that post-traumatic hypogonadism adversely 
impacts disability, functional independence, cognition, and global neurological 
outcome.6,9–11 Hypogonadism manifests with physical symptoms and functional limitations 
in men across a wide age-range.43 Therefore, it is not surprising that post-traumatic 
hypogonadism impedes recovery post-TBI. Preclinical experiments report mixed effects of 
testosterone on brain injury recovery.44 Testosterone is a precursor of estradiol, a well-
established neuro-protective agent.44 Better neurological outcomes in the non-PHH group 
potentially may be explained by either direct or downstream effects of testosterone on brain 
function. It was reported previously that PHH was associated with worse cognitive test 
scores6; however, the study did not correct for normal variance in the general population. 
The present study used norm-referenced cognitive data and yielded no difference in 
cognitive test scores. However, despite no cognitive differences based neuropsychological 
testing, participants with PHH reported a clinically meaningful difference in functional 
cognition compared to those without hypogonadism.45 These findings may, in part, be due to 
increased fatigue (lack of energy endorsement) reported in the PHH group. Individuals with 
PHH may have the cognitive ability to perform within similar limits on cognitive testing as 
those without PHH, however decreased effort in applying cognitive skills to everyday tasks 
may impede functional cognition. Further study with a larger sample may allow for more 
detailed analysis of individual cognitive testing domains where finer differences may be 
observed. No between group differences were detected with depression (PHQ-9 scores 
ranged from ~4–7 points) or PQOL (scores range from ~57%-74%), findings which may be 
due to already poor baseline scores post-TBI for which PHH does not further discriminate. 
Future work should evaluate if/how fatigue influences functional cognition and other 
multidimensional outcomes using a Rehabilomics approach, which applies grounded 
methodologies for assessing biomarker relationships with complications/conditions arising 
from injury, and relating how these relationships affect multimodal outcome.46,47
Age is important to consider when studying hypogonadism. Testosterone levels naturally 
decline in men starting around age 30 at a rate of ~1% per year.48 The PHH group’s median 
age was 11 years older than the non-PHH group, however, PHH showed stronger prognostic 
ability to discriminate multimodal outcomes after controlling for age than in bivariate 
analysis. These findings suggest that outcome differences are primarily due to 
hypogonadism, independent of age. Higher DAI rates in the non-PHH group is consistent 
with observations that younger age is associated with DAI after TBI.49,50 Also, multivariable 
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analyses showed that lack of energy endorsement was age-driven at 6 months but PHH-
driven at 12 months. This may suggest that age has a particularly heavy influence on energy 
levels earlier during the recovery process. This finding could also reflect that low 
testosterone levels take a longer time-frame to manifest with noticeable fatigue symptoms.
A published consensus guideline recommends withholding hypogonadism therapy until 1 
year post-TBI since deficits may self-correct between 3–12 months.32 However, new deficits 
may also arise in this timeframe.51,52 Our data show that low testosterone levels persist over 
time and measurable outcome differences already exist at 6 and 12 months post-injury. Thus, 
hypogonadism is a clinically important problem in this timeframe that may warrant 
treatment. In our post-hoc cross-sectional analysis, some individuals with PHH had normal 
hormone levels based on the HH definition at 6 and 12 months. However, at 6 and 12 
months, those meeting HH criteria were not significantly different than those with 
testosterone in the normal range on any outcome measure assessed, suggesting that 
persistence of HH over time is what contributes to health outcomes and recovery at these 
later time points.
Thus, we developed a prediction model of PHH, hypothesizing that earlier intervention may 
improve health outcomes and recovery during the first year post-injury. A clinical testing 
protocol to predict post-traumatic hypogonadism should be conservative considering there is 
no published clinical trial of hormone replacement therapy for this population. Clinical 
characteristics do not sufficiently predict PHH, so testosterone measurements were utilized, 
yielding 79% sensitivity and 100% specificity. The 79% sensitivity is sufficient considering 
post-traumatic hypogonadism is largely either not recognized by clinicians or undertreated, 
as evidenced by our data showing that no men were being treated with testosterone during 
follow-up. Two-step testing enabled elimination of false-positives, and identified men with 
PHH that would qualify for treatment without the risk of treating an individual needlessly. 
This work represents a novel prediction algorithm to screen for post-traumatic 
hypogonadism, although we cannot yet make any definitive treatment recommendations. 
These results must be validated in an independent study that also evaluates for evidence of 
other concurrent neuroendocrinopathy. If validated, however, the current data showing 
association between PHH and poor outcome, combined with this PHH prediction method, 
could provide a rationale for a clinical trial of hormone replacement therapy in men with 
hypogonadism after severe TBI.
Other endocrinopathies can occur after TBI in isolation or in the setting of 
hypogonadism7,36,53. Thus, those in either the PHH group or the no-PHH group could be at 
risk for other neuroendocrinopathies after TBI. In 322 men with TBI screened for 
hypopituitarism upon presentation to a neurorehabilitation facility (median 7wks post-TBI), 
131 (40%) were hypotestosteronemic, and 28 of these men (21%) had disturbances in at 
least one other pituitary axis.7 Therefore one must consider this study’s results within the 
clinical likelihood that multiple axes are affected. Notably, many hormones can directly 
influence testosterone levels. Experimentally elevated serum cortisol rapidly decreases 
testosterone levels in men,54 which in vitro experiments suggest is due to direct 
glucocorticoid inhibition of testicular testosterone synthesis.55 In our population there was 
no association between endogenous serum cortisol levels and PHH status (data not shown), 
Barton et al. Page 9













however, more work with stimulated cortisol responses would be needed to draw a definitive 
conclusion about the HPA axis’ role in HPG suppression. Primary hypothyroidism in men is 
associated with HH that is reversible with thyroxine replacement.56 Lastly, 
hyperprolactinemia in male rats decreases gonadal testosterone synthesis and pituitary LH 
release.57,58 Notably, Kopczak reported that 30% of men with post-traumatic 
hypotestosteronemia also had hyperprolactinemia.7 A complete, systematic temporal 
characterization of these hormone levels after TBI is lacking, but is an important topic for 
ongoing research.
We have devised a preliminary assessment protocol, based on our work and the literature, 
regarding possible involvement of other hypothalamic-pituitary axes to identify individuals 
with PHH who may benefit from hormone replacement therapy, should clinical trials 
demonstrate such a benefit (Figure-3).
There are limitations associated with this study. PHH status was assigned retrospectively and 
not clinically diagnosed. We did not determine if PHH was due to hypothalamic or pituitary 
dysfunction, however, hypothalamic vs. hypopituitary hormone dysfunction would not likely 
impact clinical decision making for treatment. Serum samples and outcome measures were 
unable to be collected at all time-points for individuals, representing a challenge of 
conducting long-term prospective studies. We also did not measure free testosterone or sex 
hormone binding globulin, which may further inform hypogonadism in men.8 However, our 
findings show a strong, clinically relevant relationship between injury, serum testosterone 
levels over time, and patient outcomes.
In conclusion, men with PHH exhibit poorer outcomes at 6 and 12 months after TBI. 
Accurate clinical testing for PHH can be performed at 12–16 weeks post-TBI, suggesting 
men may benefit from screening. However before clinical treatment recommendations can 
be made, this algorithm requires: 1) validation in an independent population, and 2) rigorous 
testing in a placebo-controlled randomized control trial. Future work should also examine 
other pituitary hormone axes, and determine whether these conclusions about PHH 
generalize to mild/moderate TBI populations. Importantly, the impact of post-traumatic 
hypogonadism on outcome in women remains unknown and requires study.
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Serum levels of testosterone (upper) and LH (lower) by persistent hypogonadotropic 
hypogonadism (PHH) status after severe TBI in men. Data represent mean ± SEM. 
Testosterone levels were significantly lower in the PHH group at week 1 (p<0.05) and weeks 
6–52 (p<0.001). LH levels were significantly lower in the PHH group at weeks 10, 12 
(p<0.05), 14 (p<0.01), 16, and 24 (p<0.05).
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A: Receiver operating characteristic (ROC) curve analysis for initial screening test of 
testosterone serum values to predict PHH status. The 100% sensitivity cutoff point was 
selected (13.47 nmol/L). Subjects testing positive (below the cutoff) in the screening test 
were analyzed in a confirmatory test. B: ROC curve analysis for confirmatory test of 
testosterone serum values to predict PHH status. The 100% specificity cutoff point was 
selected (9.05 nmol/L). Two-step testing of serum testosterone yielded an overall sensitivity 
of 78.6% and specificity of 100% for prediction of PHH.
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Diagnosis of post-traumatic hypogonadotropic hypogonadism should be incorporated into a 
full endocrinological workup for hypopituitarism in order to determine an appropriate course 
of therapy. Adrenal insufficiency, hypothyroidism, and hyperprolactinemia should all be 
treated prior to hypogonadism since these hormones may affect testosterone levels. In the 
absence of these endocrinopathies, two-step testosterone testing is recommended to detect 
persistent hypogonadotropic hypogonadism (PHH). This should be conducted between 12–
16 weeks after TBI. If a testosterone screening test level is below 13.5 nmol/L, then a second 
confirmatory test should be conducted. If the confirmatory test level is below 9.05 nmol/L, 
then this individual is at risk for poor outcome, and treatment for PHH may be beneficial.
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Table 1
Demographics and clinical characteristics
All Non-PHH PHH p-value
n 78 44 34 -
Age, median (IQR), y 29 (22–42) 24 (21–40) 35 (22–42) 0.044
BMI, median (IQR), kg/m2 26 (24–29) 26 (24–29) 27 (24–30) 0.343
Education, No. (%)
 < HS 14 (18) 15 (34) 13 (41) 0.242
 HS 34 (45) 23 (52) 11 (34)
 > HS 28 (37) 6 (14) 8 (25)
Race, No. (%)
 Caucasian 72 (92) 40 (91) 32 (94) 0.815
 African American 4 (5) 3 (7) 1 (3)
 Other 2 (3) 1 (2) 1 (3)
GCS (best in 24 h), median (IQR) 7 (6–9) 7 (6–9) 7 (6–9) 0.782
Injury severity score, median (IQR) 30 (26–38) 30 (26–38) 30 (25–39) 0.541
Length of hospital stay, median (IQR) 20 (16–27) 19 (15–26) 23 (18–35) 0.076
Mechanism of injury, No. (%)
 Motor vehicle accident 39 (51) 26 (61) 13 (39) 0.173
 Motorcycle accident 22 (29) 11 (26) 11 (33)
 Fall/jump 12 (16) 4 (9) 8 (24)
 Bicycle accident 3 (4) 2 (5) 1 (3)
Radiographic Injury Type, No. (%)
 Subdural hematoma 47 (62) 26 (59) 21 (66) 0.563
 Subarachnoid hemorrhage 49 (65) 28 (64) 21 (66) 0.858
 Diffuse axonal injury 18 (24) 16 (36) 2 (6) 0.002
 Epidural hemorrhage 10 (13) 6 (14) 4 (13) 1.000
 Contusion 26 (24) 14 (32) 12 (38) 0.606
 Intraventricular hemorrhage 15 (20) 9 (21) 6 (19) 0.854
 Intracerebral hemorrhage 26 (34) 13 (30) 13 (41) 0.315
 Other 4 (5) 2 (5) 2 (6) 1.000
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Table 2





Non-PHH PHH p value
Favorable (4 or 5), no. (%) 29 (67) 14 (45) 0.055
Unfavorable (2 or 3), no. (%) 14 (33) 17 (55)
DRS, median (IQR) 73 3 (1–5) 5 (1–9) 0.084
FIM-Total, median (IQR) 71 123 (117–124) 117 (80–122) 0.011
FIM-Cog, median (IQR) 71 32 (29–34) 29 (13–32) 0.007
Cognitive composite, mean ± SD 53 40.4 ± 6.0 40.7 ± 7.8 0.867
Depression 51
Depressed, no. (%) 9 (28) 7 (41) 0.354
Not depressed, no. (%) 23 (72) 10 (59)
Lack of energy (PHQ-9 Q4), mean ± SD 51 .62 ± .92 .83 ± .99 0.409
Percent back to normal, median (IQR) 43 77 (50–89) 60 (40–75) 0.132
Perceived quality-of-life, median (IQR) 45 78 (49–88) 58 (46–82) 0.173
12 months
GOS 67
Favorable (4 or 5), no. (%) 32 (84) 19 (66) 0.075
Unfavorable (2 or 3), no. (%) 6 (16) 10 (34)
DRS, median (IQR) 66 1 (0–4) 3 (1–7) 0.010
FIM-Total, median (IQR) 63 124 (121–125) 117 (105–122) 0.002
FIM-Cog, median (IQR) 59 33 (31–34) 28 (22–32) 0.001
Cognitive Composite, mean ± SD 47 43.2 ± 5.9 40.5 ± 7.3 0.163
Depression 51
Depressed, no. (%) 8 (24) 6 (33) 0.525
Not depressed, no. (%) 25 (76) 12 (67)
Lack of energy (PHQ-9 Q4), mean ± SD 51 .55 ± .75 1.2 ± 1.0 0.028
Percent back to normal, median (IQR) 44 80 (50–95) 80 (50–90) 0.871
Perceived quality-of-life, median (IQR) 46 81 (61–91) 88 (58–94) 0.981
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